The two-day National Consultative Strategic Planning Workshop for the Regulatory Strategic Plan 2026–30 concluded with comprehensive stakeholder inputs that will be consolidated into the National Strategic Plan. Participants agreed on a unified direction to strengthen regulatory capacity, quality management, and public health outcomes across Pakistan.
Senior leadership at the workshop included Mr. Hamed Yaqoob Sheikh, Federal Secretary Ministry of NHSR&C; Dr. Obaidullah, CEO DRAP; Ms. Ellen Thom, Deputy WHO Representative; and Prof. Dr. Ayesha Majeed Isani, Director General Health. Public health and governance perspectives were deepened by contributions from Prof. Dr. Shahzad Ali Khan, Vice Chancellor HSA, and Mr. Ayaz Kiani, Senior Consultant Public Health, guiding technical discussion and priority setting for the Regulatory Strategic Plan.
Representatives from DRAP, Provincial Drug Control Authorities, CDCs, Secretary PQCBs, academia, QMS focal points, and major industry associations including PPMA, Pharma Bureau, HDAP, HCPA, PNMA, and PEMDA took part in shaping a cohesive national vision. Development partners WHO, UNDP, SIFC, and RCCI provided programme support and helped align proposed actions with international best practice.
The workshop was delivered through close coordination between DRAP and partner institutions, supported by a core organising team comprising Mr. Ajmal Sohail Asif, Mr. Mehmood Anwar (WHO), Mr. Asadullah (WHO), Dr. Hasan Afzaal, Dr. Haseeb Tariq, Mr. Ayub Naveed, Mr. Ammar Ashraf Awan, and Mr. Abdul Mughees. Their efforts ensured focused sessions that captured achievements, identified gaps, and prioritised practical steps for implementation.
With consolidated inputs now to be drafted into a final National Strategic Plan for 2026–30, stakeholders emphasised the need for a resilient, trusted, and globally aligned regulatory system that safeguards medicine quality and public health in Pakistan. The Regulatory Strategic Plan will guide coordinated actions across institutions and partners as the country moves toward stronger regulation and safer medicines.
